title: A 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade.
abstract: OBJECTIVE
  The aim of this study was to assess the epidemiology of candidemia and antifungal susceptibility profiles of Candida isolates in Italy through a prospective surveillance study and to evaluate changes compared to a previous survey performed in one Italian region (Lombardy) in 1997-1999.
  
  
  METHODS
  A prospective laboratory-based surveillance of candidemia was performed in Italy from January to December 2009. For each case a questionnaire was filled in, and the first isolate was collected and tested for in vitro antifungal susceptibility.
  
  
  RESULTS
  During our 12-month survey, 467 episodes of candidemia were reported from 34 centres (30 located in Lombardy) and 464 isolates collected. Candida albicans was the predominant species (overall incidence 50.4 %), but the proportion varied considerably from 52.1 % in Lombardy hospitals to 45.2 % hospitals located outside this region. The second most frequent species was C. glabrata in Lombardy and C. parapsilosis in other regions. Comparison of the 1997-1999 and 2009 data on episodes of candidemia in Lombardy revealed a threefold increase in incidence (from 0.38 to 1.19 per 1,000 admissions), aging of infected patients, decline in crude mortality (from 35 to 27.1 %) and an increased proportion of C. glabrata etiology (from 12.8 to 20.3 %). Susceptibility testing confirmed the broad activity of amphotericin B and echinocandins. Decreased susceptibility to fluconazole was found in 24.9 % of the tested isolates.
  
  
  CONCLUSIONS
  The results of this latest survey confirm the high rate of candidemia in Italy and show changes in some of the epidemiological tracts, such as aging of infected patients, increased proportion of C. glabrata infections, increased diagnosis in medical wards, and improvement in patients' survival.
authors.affiliation: Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Via Pascal 36, 20133, Milan, Italy. annamaria.tortorano@unimi.it
authors.forename: A M
authors.initials: AM
authors.lastname: Tortorano
authors.forename: A
authors.initials: A
authors.lastname: Prigitano
authors.forename: C
authors.initials: C
authors.lastname: Lazzarini
authors.forename: M
authors.initials: M
authors.lastname: Passera
authors.forename: M L
authors.initials: ML
authors.lastname: Deiana
authors.forename: S
authors.initials: S
authors.lastname: Cavinato
authors.forename: C
authors.initials: C
authors.lastname: De Luca
authors.forename: A
authors.initials: A
authors.lastname: Grancini
authors.forename: G
authors.initials: G
authors.lastname: Lo Cascio
authors.forename: C
authors.initials: C
authors.lastname: Ossi
authors.forename: E
authors.initials: E
authors.lastname: Sala
authors.forename: M T
authors.initials: MT
authors.lastname: Montagna
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000935:Antifungal Agents / Q000494:pharmacology; D002175:Candida / Q000187:drug effects / Q000302:isolation & purification; D058387:Candidemia / Q000453:epidemiology* / Q000382:microbiology; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007558:Italy / Q000453:epidemiology; D008297:Male; D008826:Microbial Sensitivity Tests; D015995:Prevalence; D011446:Prospective Studies
chemical_list: D000935:Antifungal Agents
references.citation: J Chemother. 2012 Feb;24(1):61-3
references.pmid: 22546727
references.citation: Drug Resist Updat. 2010 Dec;13(6):180-95
references.pmid: 21050800
references.citation: Clin Microbiol Infect. 2008 May;14(5):487-94
references.pmid: 18294241
references.citation: Diagn Microbiol Infect Dis. 2012 May;73(1):45-8
references.pmid: 22578938
references.citation: J Clin Microbiol. 2010 Nov;48(11):4200-6
references.pmid: 20826636
references.citation: Antimicrob Agents Chemother. 2001 Sep;45(9):2475-9
references.pmid: 11502517
references.citation: Antimicrob Agents Chemother. 2011 Feb;55(2):532-8
references.pmid: 21078946
references.citation: Diagn Microbiol Infect Dis. 2007 May;58(1):77-82
references.pmid: 17368800
references.citation: PLoS One. 2011;6(9):e24198
references.pmid: 21935385
references.citation: Clin Infect Dis. 2012 Nov 15;55(10):1352-61
references.pmid: 22893576
references.citation: Int J Antimicrob Agents. 2006 May;27(5):359-66
references.pmid: 16647248
references.citation: Drug Resist Updat. 2011 Jun;14(3):164-76
references.pmid: 21353623
references.citation: J Hosp Infect. 2002 Aug;51(4):297-304
references.pmid: 12183145
references.citation: Clin Infect Dis. 2004 Feb 1;38(3):311-20
references.pmid: 14727199
references.citation: J Antimicrob Chemother. 2007 Aug;60(2):424-8
references.pmid: 17562683
references.citation: Clin Microbiol Rev. 2007 Jan;20(1):133-63
references.pmid: 17223626
references.citation: Mycoses. 2011 Nov;54(6):531-7
references.pmid: 20707848
references.citation: Infection. 2013 Feb;41(1):129-34
references.pmid: 23212461
references.citation: Int J Infect Dis. 2010 Nov;14(11):e954-66
references.pmid: 20797887
references.citation: J Clin Microbiol. 2011 Jan;49(1):325-34
references.pmid: 20980569
references.citation: Clin Microbiol Infect. 2007 Nov;13(11):1072-6
references.pmid: 17725647
references.citation: Clin Microbiol Infect. 2008 Feb;14(2):193-5
references.pmid: 18070130